Ingevity Corporation NGVT
$68.25
-$1.16-1.67%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.16B | 1.18B | 1.17B | 1.18B | 1.18B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.16B | 1.18B | 1.17B | 1.18B | 1.18B |
| Cost of Revenue | 683.20M | 711.80M | 706.20M | 696.00M | 699.00M |
| Gross Profit | 477.10M | 465.90M | 461.40M | 479.80M | 477.50M |
| SG&A Expenses | 165.40M | 170.00M | 171.20M | 167.80M | 161.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 875.80M | 909.90M | 905.80M | 891.30M | 887.30M |
| Operating Income | 284.50M | 267.80M | 261.80M | 284.50M | 289.20M |
| Income Before Tax | 37.80M | -149.50M | -142.10M | -12.70M | -20.90M |
| Income Tax Expenses | 12.60M | 6.50M | 8.20M | 39.20M | 24.30M |
| Earnings from Continuing Operations | 25.20 | -156.00 | -150.30 | -51.90 | -45.20 |
| Earnings from Discontinued Operations | 28.80M | 28.20M | -16.80M | -14.00M | -171.40M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.00M | -127.80M | -167.10M | -65.90M | -216.60M |
| EBIT | 284.50M | 267.80M | 261.80M | 284.50M | 289.20M |
| EBITDA | 380.20M | 367.40M | 364.90M | 385.00M | 390.30M |
| EPS Basic | 1.54 | -3.49 | -4.63 | -1.80 | -5.94 |
| Normalized Basic EPS | 3.51 | 3.14 | 2.93 | 6.07 | 6.08 |
| EPS Diluted | 1.46 | -3.56 | -4.66 | -1.83 | -5.94 |
| Normalized Diluted EPS | 3.45 | 3.10 | 2.90 | 6.04 | 6.07 |
| Average Basic Shares Outstanding | 141.96M | 143.73M | 144.85M | 145.48M | 145.51M |
| Average Diluted Shares Outstanding | 143.95M | 145.14M | 145.78M | 146.40M | 145.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |